Osteoarthritis (OA) remains one of the most common and challenging conditions encountered in small animal practice. For decades, NSAIDs have been the cornerstone of OA management, offering effective pain relief and anti-inflammatory benefits. However, concerns about long-term safety, particularly gastrointestinal, renal, and hepatic side effects, have prompted veterinarians to explore complementary or alternative therapies. One such modality gaining traction is pulsed electromagnetic field (PEMF) therapy.

Study Overview

A recent randomized, controlled pilot study compared PEMF therapy with the NSAID Mavacoxib in 16 dogs diagnosed with OA both clinically and radiographically. Dogs were randomly assigned to either:

• A 12-session PEMF protocol delivered over 45 days
• A standard Mavacoxib regimen

Clinical evaluations included pain scores (VAS), pain on palpation, lameness severity (NRS), gait analysis (GLS and TPI), muscle circumference, and radiographic progression. Assessments were conducted at baseline (T0), 30 days (T1), and 60 days (T2).

Key Findings

• Pain reduction: Dogs receiving PEMF showed earlier improvements in pain scores compared to those on NSAIDs.
• Lameness improvement: PEMF-treated dogs demonstrated quicker and more sustained reductions in lameness severity.
• Muscle mass: Increases in muscle circumference were noted in the PEMF group, suggesting better mobility and use of affected limbs.
• Joint mobility: A favorable trend was observed in PEMF dogs, though not statistically significant.
• Gait and radiographic progression: No significant differences were detected between groups.

Importantly, PEMF therapy was well tolerated, with no adverse reactions reported.

Clinical Implications

This pilot study suggests that PEMF therapy may be non-inferior to NSAIDs in managing canine OA. For veterinary professionals, this opens the door to considering PEMF as part of a multimodal management strategy, especially for patients where NSAID use is contraindicated or requires cautious monitoring.

Potential advantages of PEMF

• Absence of systemic side effects
• Suitability for long-term use
• Potential synergistic role alongside pharmacological and physical therapies

Takeaway for Veterinary Practice

PEMF therapy represents a promising adjunct or alternative to NSAIDs in canine OA management. While NSAIDs remain indispensable for many patients, PEMF may offer earlier improvements in pain and mobility without the risks associated with chronic drug use. For veterinarians, integrating PEMF into treatment plans could enhance patient outcomes, particularly in cases where NSAID therapy is limited by comorbidities or owner concerns.